Which of the following should be considered when using morphine in the treatment of a patient with end-stage COPD?

While there is concern about the use of opioids like morphine potentially shortening life, this statement oversimplifies the effects of morphine. In carefully managed doses, morphine can provide significant symptom relief and may not necessarily hasten death; rather, it can improve comfort during the end stages of disease.

This statement is misleading as morphine can actually depress respiratory drive, leading to an increase in carbon dioxide levels rather than a decrease. While respiratory depression is a known side effect, it is important to note that in controlled doses, morphine can help alleviate distress caused by dyspnea without overly compromising respiratory function.

This choice incorrectly suggests that bronchodilators and steroids alone can manage all symptoms of end-stage COPD. While these medications are essential for managing airflow obstruction and inflammation, they do not address severe dyspnea effectively in all patients, where morphine can play a critical role in symptom management.